Dow jumps over 300 points shortly after opening

Xinhua
04 May 2021, 02:05 GMT+10

NEW YORK, May 3 (Xinhua) -- U.S. stocks kicked off the first trading session of May on a strong note, with the Dow up more than 300 points on Monday morning.

Shortly after the opening bell, the Dow Jones Industrial Average jumped 336.70 points, or 0.99 percent, to 34,211.55. The S&P 500 added 27.25 points, or 0.65 percent, to 4,208.42. The Nasdaq Composite Index rose 30.96 points, or 0.22 percent, to 13,993.64.

Ten of the 11 primary S&P 500 sectors advanced in morning trading, with energy up 1.9 percent, leading the gainers. Real estate slipped 0.4 percent, the lone declining group.

Stocks tied to economic reopening such as cruise lines and retailers traded on an upbeat note.

For the week ending Friday, the Dow fell 0.5 percent, the S&P 500 eked out a gain of 0.2 percent, and the Nasdaq Composite declined 0.4 percent, as Wall Street digested a big wave of earnings reports from tech giants and a key statement from the Federal Reserve.

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Kolkata Sun.

More Information

33 ℃

Partly Cloudy in Kolkata/Bose

International

Section

More than 200 Palestinians injured during end-of-Ramadan clashes

JERUSALEM - Celebrating the final week of Ramadan, thousands of Palestinian worshippers at the Al-Aqsa Mosque gathered for prayer time ...

U.S. announces waiver of Covid patents; pharmaceutical stocks tumble

WASHINGTON D.C.: Shares of Covid vaccine manufacturers fell following statements from the White House that they support waiving patent rights ...

U.S. economic downturn translates to lowest birth rate in 40 years

WASHINGTON DC - Amidst the radical turndown in the American economy during the Covid lockdown, birth rates in the United ...

WHO says "low confidence" in Sinopharm Covid side-effects data

GENEVA, Switzerland: World Health Organization experts have said they have "very low confidence" in data received from Chinese state-owned drugmaker ...